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ABSTRACT

Beenen, Timothy J. M.S., Purdue University, May 2015. In Vivo Analysis of a Salt
Bridge at the External Gate of the Drosophila Melanogaster Serotonin
Transporter in Response to Amphetamines. Major Professor: Eric Barker.
Monoamine neurotransmitter transporters are membrane proteins
responsible for the clearing of biogenic amines from a synapse. These
transporters are targets for many important pharmaceuticals including
antidepressants, as well as psychostimulant drugs such as cocaine and
amphetamines. Amphetamines are believed to elicit their psychostimulant activity
primarily by inducing a reversal of the transport cycle and increasing
neurotransmitter release into the synapse, though the mechanism of this activity
is incompletely understood. Previous in vitro research has suggested functional
significance of a conserved salt bridge in the serotonin transporter (SERT) in
amphetamine-induced 5-HT efflux. This salt bridge is disrupted in the Drosophila
melanogaster SERT. Here, a mutant line of D. melanogaster expressing a SERT
with a restored salt bridge (dSERT N484D) was studied. Changes in
neurochemistry induced by methamphetamine (METH) or 3, 4methylenedioxymethamphetamine (MDMA) were examined in vivo. HPLC/Mass
spectrometry was used to quantify brain concentrations of neurotransmitters in fly
tissue after drug treatment. N484D flies were found to have significantly depleted
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5-HT in response to 0.05% MDMA relative to wild-type. This depletion of
5-HT was not observed after treatment with 0.6% MDMA or 0.6% METH. No
significant drug-induced changes were observed in concentrations of other
neurotransmitters examined. The results show that the presence of the salt
bridge at the external gate of SERT may be important for amphetamine-induced
5-HT efflux, and helps explain pharmacological differences observed between
hSERT and dSERT.
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CHAPTER 1. INTRODUCTION

1.1

History of MDMA and methamphetamine
MDMA

MDMA (N-methyl-1-(3, 4-methylenedioxyphenyl)-propan-2-amine), also
known as ecstasy, is a psychostimulant drug that induces powerful psychoactive
experiences in humans (figure 1.1). MDMA was first synthesized in 1912 by the
Merck Corporation as an intermediary product intended for the synthesis of 3methyl-hydrastinine, an anti-hemorrhagic drug. Merck patented MDMA as a part
of this reaction, though no application of the patent was ever utilized by the
company.1 Years after its discovery the psychoactive properties of MDMA
became better known. MDMA shares both structural and psychoactive
commonalities with psychostimulant drugs such as methamphetamine, as well as
psychedelics such as mescaline and LSD.2 The subjective experience of MDMA
use includes feelings of euphoria, stimulation, a sense of wellbeing,
communicativeness, and visual hallucinations.3 Drugs that produce subjective
experiences of this sort are considered to be members of a unique group, and
the special term “entactogen” has been conceived to describe and classify them.4
Recreational use of MDMA first rose in popularity during the 1960s and
1970s amongst members of the western counterculture. By the 1980s MDMA
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had become a staple drug used at night clubs and rave parties. The stimulant
effects of MDMA suppress a person’s perception of the need to consume food or
water. Consequently, MDMA use—particularly in the context of all-night dance
parties—earned repute for risk of injury or death by dehydration.5
During the 1970s and early 1980s, MDMA found medical application as an
adjunct to psychotherapy in individuals suffering from depression and posttraumatic stress disorder.1, 4 More recently, interest in use for such applications
has reemerged.6 However, earlier research had suggested that the MDMA
metabolite MDA is toxic to humans, and other investigations pointed to the high
likelihood that the MDMA being consumed as a street drug was often
dangerously impure. Based on this, in 1984, the Drug Enforcement Agency of the
United States classified it as a schedule 1 controlled substance. Schedule 1
classification indicates that a drug has a high abuse potential, without any
accepted medical value and, as a result, medical use of MDMA was promptly
halted. This scheduling came as a consequence of the DEA being given
emergency drug scheduling authority. Despite this classification being contested
as inappropriate for MDMA by psychiatrists, researchers, and courts,7, 8 this
regulatory status was ultimately upheld in the United States in 1988, after a four
year legal battle.9 Subsequent studies have shown that MDMA does cause an
acute neurodegeneration of serotonergic neurons.4, 10 However, debate still
persists in the medical community regarding the mechanisms by, and, extent to
which MDMA may induce chronic neurotoxicity or neurodegeneration. 4, 11, 12, 13, 14
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METH
Methamphetamine (N-methyl-1-phenylpropan-2-amine) is a powerful
stimulant drug with great potential for abuse and addiction (figure 1.1).15
Methamphetamine (METH) use induces feelings of euphoria, intense arousal,
increased libido, and reduced appetite and fatigue. 5, 16, 17 A structural derivative
of amphetamine, METH was first synthesized from ephedrine in 1919 by
Japanese pharmacologist Nagai Nagayoshi.16 In subsequent years the drug was
used medically for its appetite-suppressing and wakefulness-promoting effects.
As the potential for addiction became better known, METH was classified as a
schedule 2 controlled substance in the United States in 1970. Today, legal efforts
have reduced the availability of chemical precursors commonly used for METH
production (most notably pseudoephedrine), yet the drug is still extensively
produced and abused illegally. The quality and purity of illicitly-produced METH
varies widely, and the side effects of potential contaminants are unknown.16
Despite its notoriety for addiction, METH has accepted medical indications for the
treatment of exogenous obesity and attention deficit disorder with hyperactivity.
When used for these purposes it is marketed under the brand name Desoxyn.16,
18

METH use, and particularly chronic use, is associated with numerous
health deficits, including cardiomyopathy, psychosis, degradation of teeth and
enamel, depression, sleep disturbances, reproductive dysfunction, oxidative
stress and abnormal metabolism.11, 15, 17, 19 Amphetamines are used around the
world, and their abuse is quite prevalent. Use and abuse of amphetamines is a
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global phenomenon, with approximately 17.2 million people dependent as of
2010. Worldwide amphetamine dependence is also increasing, especially in
Asia.20

A. MDMA

B. METH

Figure 1.1 Structure of 3,4-methylenedioxymethamphetamine (MDMA) and
methamphetamine (METH)

1.2

The serotonin transporter

Serotonin (5-hydroxytryptamine; 5-HT) is a neurotransmitter responsible for
many biological functions including regulation of sleep, libido, appetite, and
memory. 5-HT signaling is governed by several systems including ion channels,
pre and post-synaptic receptors, biosynthetic enzymes, and transporters.21
The serotonin transporter (SERT) is a pre-synaptic membrane protein.
SERT is a member of the solute carrier 6 (SLC6) family of transporters, and is
responsible for the clearing of 5-HT from the synaptic cleft, thereby terminating 5HT neurotransmission.22,23, 24 SLC6 transporters are 12-transmembrane alphahelical membrane proteins. They are neurotransmitter-sodium symporters
(NSSs), which couple the “downhill” transport of sodium to the “uphill” transport
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of their substrate. This family includes the monoamine transporters SERT, the
dopamine transporter (DAT), the norepinephrine transporter (NET), three GABA
transporter (GATs), 2 glycine transporters (GLYs), and a subset of amino acid
transporters.24
During normal neurotransmission, neurotransmitters such as dopamine
(DA), norepinephrine (NE), and 5-HT are released from pre-synaptic neurons into
the synapses via vesicles. These particular neurotransmitters are monoamines,
and are known to play an important role in normal rewarding and reinforcing
behaviors. However, drugs of abuse utilize these same neurotransmitter systems,
leading to their addictive potential.25
Upon being released, these neurotransmitters can bind to their target
receptors on post-synaptic neurons, thereby propagating a chemical signal. After
a neurotransmitter has been released into a synapse and has transmitted its
chemical signal, it is brought back into a pre-synaptic cell via a transporter. Once
inside a cell, a monoamine neurotransmitter is either broken down by a
monoamine oxidase (MAO) or repackaged into a vesicle by the vesicular
monoamine transporter (VMAT) for subsequent reuse.23 (Figure 2A)
SERT is an important target for many pharmaceuticals, including most
antidepressants, as well as notable drugs of abuse such as cocaine, and
amphetamines.26 As serotonin is critically involved in the regulation of mood,
arousal, appetite, and libido, it naturally became the subject of research in the
treatment of depression and anxiety disorders.27 During the 1960s the
antihistamine drug diphenhydramine was discovered to have serotonin reuptake
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inhibiting effects. This observation led to a search for structural derivatives of
diphenhydramine that would have more specific effects on SERT. This search
culminated in a class of drugs that would come to be known as selective
serotonin reuptake inhibitors (SSRIs). SSRIs include antidepressants such as
sertraline and fluoxetine, which are now some of the most prescribed
pharmaceuticals.28 Eli Lilly developed the drug fluoxetine during the 1970s, which
was brought to market in the United States in 1987, and marketed under the
brand name Prozac.27 Much progress has been made in understanding the
mechanisms of antidepressant pharmacology in the decades following their initial
discovery.29 Unipolar depression is an extremely debilitating mental illness, and
is currently increasing in prevalence globally. It has been projected that by 2020
unipolar depression will be the second most burdensome disease behind
ischemic heart attack.20, 30 It is likely that as rates of mental illnesses diagnosed
increase, use of SSRIs will increase as well. Thus, it is important to continue to
study the targets of these drugs to increase understanding of their pharmacology,
and improve available medication therapies.

1.3

Amphetamine action on monoamine systems
Molecular pharmacology of psychostimulants

Amphetamines exert their action by being transported into presynaptic
neurons and inducing a reversal of the transport cycle of the biogenic amine
transporters. Primary targets are SERT, DAT, NET, and VMAT. By doing so,
amphetamines increase synaptic concentrations of 5-HT, DA, and NE.31 As they
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are weak bases, amphetamines also disrupt the proton gradient required for
normal vesicular uptake, further contributing to altered transport. This mechanism
of action is unique among psychostimulants. In contrast, the action of cocaine is
mediated by its binding to the substrate-binding site of monoamine transporters,
competitively inhibiting the reuptake of monoamines.32, 33 This unique mechanism
of amphetamine action is incompletely understood, and this research aims, in
part, to further elucidate this process.
Monoamine transporters are principal targets for amphetamines. SERT is
the primary molecular target for MDMA, although MDMA also acts on DAT, likely
contributing to the subjective experience of the drug.34 In addition to inducing
neurotransmitter release through effects on transporters, MDMA may also
interact with biogenic amine receptors, further contributing to its mechanism of
action.19, 31 METH acts on monoamine amine transporters as well, but is much
less selective for SERT than MDMA, and has considerably greater affinity for
DAT and NET. METH induces the release of NE twice as much as it does DA,
and sixty times more than it does 5-HT.19, 35 Additionally, MDMA and METH are
both agonists of the trace amine associated receptor (TAAR1). Activation of
TAAR1 by its native ligands is associated with excitation of the sympathetic
nervous system. 36 Agonism of TAAR1 by amphetamines has similar effects, and
also increases DAT efflux and transporter internalization. 37 Amphetamines are
able to induce their effects on numerous pathways, primarily through action on
monoamine systems, and especially catecholamine and 5-HT transporters.
Amphetamine action on catecholamine and 5-HT receptors is important as well,
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and activity on trace amine systems also contributes to their effects.37 The
structures of monoamine neurotransmitters pertinent to this research, as well as
a brief overview of their principal functions can be found in table A.1.

Monoamine Neurotransmitter
(DA, NE, 5-HT)

Figure 1.2 Normal transporter function. Neurotransmitters are released from
presynaptic neurons via vesicles into the synaptic space to transmit a chemical
signal by activating receptors on post-synaptic neurons and glia. Transporters
clear neurotransmitters from the synapse to terminate signaling.
Neurotransmitters can then be repackaged into vesicles by VMAT for subsequent
reuse, or broken down by MAO.
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Monoamine Neurotransmitter
(DA, NE, 5-HT)
Amphetamine (MDMA, METH)

Figure 1.3 Amphetamine action on monoamine transporters. Amphetamines
reverse the flow of neurotransmitters through transporters and inhibit
neurotransmitter uptake. Neurotransmitters are pumped out of vesicles into the
cytoplasm where transporters then mediate efflux, thereby increasing synaptic
concentration of neurotransmitters and receptor activation.
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1.4

Current problem

SERT and the external gate
A crystal structure of SERT has not been resolved, but inferences made
from the crystal structure of the leucine transporter (LeuT), a bacterial homologue
of Na/Cl-dependent neurotransmitter transporters (including SERT) from Aquifex
aeolicus revealed a number of important characteristics of transporter
architecture.38 Of note, it revealed the presence of internal and external gates in
the transporter that help to govern the transport cycle by regulating access to the
substrate binding site. This allows for regulation of transport from either side of
the membrane. More recently, a structure of the D. melanogaster dopamine
transporter (dDAT) has been reported,39 as well as mutational variants of LeuT,
in which residues involved in ligand recognition and transporter function have
been altered to their corresponding residues in mammalian biogenic amine
transporters.40, 41, 42 This structural data has illuminated much about the
mechanics of transport, and factors determining substrate binding. Additionally, it
has been instrumental in developing a homology model of hSERT.43
The external gate of NSSs, based on the crystal structure of LeuT,
contains a pair of amino acids that are able to form a salt bridge between two
transmembrane helices.38 Amino acid sequence alignment of transporters from
several species revealed the absence of one of these critical external gating
residues in dSERT. (Figure 2.3) Additionally, dSERT shows greatly reduced 5HT efflux in response to amphetamine exposure.44 These observations lead to
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the hypothesis that the lack of this conserved residue contributes to the variation
in amphetamine-induced efflux between hSERT and dSERT.
As previously stated, the primary target for amphetamines are biogenic
amine transporters. MDMA and other ring-substituted amphetamines exhibit a
particularly selective affinity for SERT due to the substitutions at the 3 and 4
positions of the phenyl ring.45 The selectivity of MDMA for the serotonin
transporter, and the resulting increasing in synaptic concentrations of serotonin,
is considered to be a significant factor in the unique “entactogenic” quality of the
drug.46 Additionally, this selectivity for SERT is thought to be partially responsible
for the reduced addictive potential of MDMA relative to other stimulant drugs. For
example, METH and cocaine are considered much more addictive than MDMA
owing to their capacity to increase synaptic DA concentrations by acting on DAT.
This activation of the DA system is an important factor in the addictive potential
of these drugs. However, the role of DA in the action of MDMA should not be
overlooked, as it also plays some role in the effects of MDMA.34
The exact mechanism for how amphetamines are able to induce reverse
transport is unclear, although mechanisms relating to phosphorylation of the Nterminus, as well as structural alterations induced by changes in pH gradient
have been proposed.47, 48, 49 Understanding the role of this salt bridge may help
to explain how amphetamines are able to induce reverse transport. Additionally,
by studying systems-scale drug effects, this work could lead to development of
novel treatments for amphetamine abusers through improved understanding of
their mechanisms of addiction and toxicity.

12

TM 1

TM 10

Figure 1.4 Model of the interaction of the residues forming the salt bridge in
monoamine transporters. This shows the amino acids forming the salt bridge in
the external gate of LeuT, consisting of R30 and D404. In hSERT the
homologous residues are R104 and D484, and in dSERT they are R99 and N484.
Adapted from 38; PDB code 2A65.
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dSERT and hSERT
The amino acid sequences of the human serotonin transporter (hSERT)
and D. melanogaster serotonin transporter (dSERT) are approximately 51%
identical.50 This sequence similarity corresponds to similarities in 5-HT
recognition and uptake of 5-HT between the D. melanogaster and mammalian
transporters. However, differences in transport of amphetamines and other
substrates between the hSERT and dSERT have been observed.51, 44 Previous
research in the Barker lab has identified a key region of SERT that appears to be
important in the molecular mechanisms of amphetamine activity. Sequence
alignment of NSSs shows a highly conserved salt bridge in the extracellular
vestibule of transporters across numerous species that is lacking in dSERT
(figure 4). dSERT is unique amongst transporters of other species examined in
that this acidic residue is highly conserved, but is a basic residue in D.
melanogaster. The salt bridge in hSERT is composed of Arginine 104 and
Glutamate 493. The homologous residues in the dSERT are Arginine 99 and
Asparagine 484. Generally, a salt bridge has a stabilizing effect on protein
structure, reducing conformational flexibility.52 The salt bridge found in
monoamine transporters is hypothesized to have such an effect, aiding in the
tight closing of the transporter and preventing the leak of neurotransmitters out of
the cell.
Additional in vitro assays were previously performed in the Barker lab
utilizing HEK-293 cells transfected with SERT salt bridge mutants. These
mutants restored the acidic residue in dSERT to the hSERT equivalent (N484D),
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Figure 1.5 Transporter sequence alignment. An acidic residue (aspartate or
glutamate, E or D) is highly conserved across monoamine transporters from
several species, but is replaced by an asparagine (N) in dSERT (bold). All
sequences obtained from www.Uniprot.org.
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and changed hSERT to the dSERT equivalent (E493N). These experiments
revealed numerous differences between hSERT and dSERT: dSERT exhibits
basal efflux of 5-HT that does not occur in hSERT. This is hypothesized to be a
consequence of the absence of the salt bridge, which likely helps to keep hSERT
closed more tightly, preventing 5-HT leak.
Amphetamine-induced efflux is greatly reduced in dSERT relative to
hSERT. Electrophysiology experiments showed that amphetamines are
substrates for hSERT, but not dSERT.51 The N484D mutation in dSERT was able
to restore amphetamine-induced currents to levels comparable to hSERT in
response to MDMA
The lack of a salt bridge likely accounts for some differences in
pharmacology observed between hSERT and dSERT.51 Altering amino acid
residues in dSERT to the corresponding residues in hSERT can make dSERT
pharmacology more like that of hSERT.53 A mutant line of D. melanogaster
(N484D) containing this salt bridge is currently being investigated in vivo. This
line of flies is not a knockout mutant, and contains both wild-type dSERT and
dSERT N484D.
Current Problem
The goal of this project was to investigate the role of a salt bridge at the
external gate of the SERT in MDMA/METH-induced neurotransmitter efflux in
vivo. 5-HT efflux is believed to be a major component underlying the effects of
these drugs. Previous in-vitro studies in our lab identified reduced amphetamineinduced efflux in dSERT relative to hSERT. These differences have been
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hypothesized to be due to the lack of this highly conserved salt bridge in D.
melanogaster.
To further investigate this problem in vivo a mutant SERT has been
generated and inserted into D. melanogaster which contains a mutation (N484D)
that restores this salt bridge. It is hypothesized that this dSERT mutation will
facilitate tighter closing of the external gate, and thus restore the amphetamineinduced efflux found in hSERT.
Significance of the Problem
The mechanisms underlying amphetamine-induced efflux are poorly
understood.54 Previous work has demonstrated that single amino acid changes in
SERT in different species are able to alter ligand binding and pharmacological
activity.53, 55, 56
In vivo experiments may reveal how this residue is able to influence
MDMA activity and amphetamine-induced changes in neurochemistry. Previous
cell based assays demonstrated the importance of this residue in in vitro drugactivity, and this work corroborates those assays using an in vivo model.
Additionally, D. melanogaster has previously been used to study genomic,
proteomic, and transcriptomic changes after exposure to METH.15 This model
could also be extended to MDMA to observe systems-level changes resulting
from MDMA-induced 5-HT depletion in N484D flies in efforts to discover new
therapeutic techniques to fight addiction and toxicity.
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CHAPTER 2. AMPHETAMINE PHARMACOLOGY IN D. MELANOGASTER

2.1

Use of D. melanogaster as a model system

Rationale for the use of D. melanogaster
Previous research in the Barker lab utilizing in vitro assays demonstrated
important pharmacological differences between dSERT and hSERT. Specifically,
it was observed that hSERT will readily efflux when exposed to amphetamines,
however dSERT has minimal response to amphetamines.51 As the conserved
acidic residue present in most monoamine transporters is an asparagine in
dSERT, an important role may exist for this residue in mediating MDMA/METH
action on SERT. Indeed, previous research in the lab, as described above,
confirmed that this gating residue plays a key role in the differences between
hSERT and dSERT in amphetamine-induced efflux.
To further understand the role of this residue, the fruit fly, D. melanogaster
was used for the study of drug action in vivo. D. melanogaster is a very suitable
and ubiquitous model organism in part because of the relative ease of husbandry,
and its well-characterized genome. Additionally, useful inferences about other
animals can be made from evaluating genetic manipulations in the fly, owing to
the high degree of homology between the two genomes.57 Capitalizing on this
genetic similarity can be useful for research, as over 75% of genes associated
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with human diseases have been found to be shared between humans and D.
melanogaster.58 Thus, using the fly for in vivo studies such as those performed
here is worthwhile and convenient.
Previous research has shown that METH produces behavioral changes in D.
melanogaster that are very similar to those observed in humans (e.g. increased
locomotion, reduced food intake, altered metabolism), making D. melanogaster
an appropriate organism for use in studying amphetamine pharmacology.59, 60
Inferences made from the impact of amphetamines in D. melanogaster can be
extended to humans as well, and are likely to assist in the development of
therapeutics to fight addiction and reduce amphetamine toxicity. For example,
METH has been found to alter carbohydrate metabolism in D. melanogaster and
this is believed to contribute to its toxicity.15 Experiments already performed have
revealed that increased dietary trehalose was able to significantly reduce METH
toxicity by attenuating a METH-induced Warburg-like effect in D. melanogaster.15,
59

Thus, further systems-scale studies hold promise to reveal additional pathways

contributing to amphetamine toxicity and its treatment.
D. melanogaster husbandry and drug administration
Wild-type (w1118 strain) and dSERT N484D mutant flies were received
from collaborator Dr. Barry Pittendrigh (University of Illinois at UrbanaChampaign). Flies were reared on the Formula 4-24® Drosophila diet (Carolina
Biological Supply, Burlington, NC) at 22-23 C and 60-70% humidity. A targeted
gene expression system under the control of TrH-GAL4 (tryptophan hydroxylase)
was used for insertion of the N484D gene. Flies were contained in capped vials
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containing holes for gas exchange and a single cotton swab by which food and
drugs were administered. Immediately upon arrival a fresh solution of 10%
sucrose was prepared as food for the flies. Control flies were given 150 µL of the
sucrose solution, and the experimental group was given 150 µL of sucrose
containing either MDMA or METH. A red dye was added to provide a means of
confirming consumption of food and drugs by visual observation of the presence
of a red pigment in the abdomen. Drug concentrations were 0.6% for METH, and
either 0.05% or 0.6% for MDMA. Both wild-type w1118, and transgenic flies
containing the N484D mutant serotonin transporter were used. Each group of
flies was then exposed to sucrose alone or sucrose with drug for different
duration of time, ranging from 2 hours to 48 hours. After the appropriate time had
passed, the experiment was terminated by promptly placing the vials of flies in a 80˚C freezer.

2.2

Isolation of D. melanogaster brain tissue

To examine changes in neurochemistry, flies were kept cold on dry ice and
were decapitated under a microscope. Males were separated from females in
order to observe potential sex-specific drug effects. Only the fly heads were used
for further analysis, and all other tissue was discarded, so as to measure only
changes in brain neurochemistry specifically.
Flies from each group were kept separately and prepared for analysis by
high-performance liquid chromatography coupled to tandem mass spectroscopy
(HPLC-MS/MS). 90µL of 0.1M formic acid and10µL of deuterated serotonin (d4-5-
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HT) internal standard was added to a 1.5mL Eppendorf tube containing
approximately 15 heads for each sample. Samples were kept cold and
homogenized using a Polytron homogenizer. After homogenization each sample
was sonicated for 60 seconds, and then stored in a -80˚C freezer until analysis
by HPLC-MS/MS.

2.3

Mass spectrometry

HPLC-MS/MS was used to identify and quantify biogenic amine
concentrations in each sample. This technique is useful because it is highly
sensitive and is able to detect very small concentrations of molecules of interest.
The technique has previously been used with success by the Barker lab.61 HPLC
separates molecules by size by forcing a sample through a column under high
pressure.
In these experiments, an internal standard of deuterated 5-HT was used for
calibration of the HPLC-MS/MS instrument, serving as a constant to quantify the
concentrations of the monoamines being analyzed in each sample. This is an
appropriate internal standard because it is similar, but not identical, to each of the
other biogenic amines being studied.
Samples were analyzed at Bindley Biosciences Center, Purdue University.
The instrument employed was an Agilent 1200 HPLC pump and an Agilent 6460
triple quadrupole mass spectrometer. The chromatography utilized a Waters
Atlantis T3 polar amide C18 HPLC column with a mobile phase of a
water/methanol gradient, buffered with 0.1% formic acid. The total run time was

21
22 minutes with an elution time of 3.8 minutes for 5-HT. The mass spectrometer
source used a positive polarity electrospray ionization process. The MRM
transitions were 177.1 to 160.1 for 5-HT and 181.1 to 164.1 for d4-5-HT.

2.4

Changes in neurochemistry

Using an in vivo model allows for the assessment of changes in many
systems, as opposed to previous in vitro work, which only examined changes in
SERT activity, specifically. Concentrations of five biogenic amine
neurotransmitters, 5-HT, DA, octopamine (OCT), NE, and tyramine (TYR) were
measured to assess for MDMA or METH-induced changes in neurochemistry in
wild-type and N484D mutant flies in vivo. Changes in concentration were
analyzed for each neurotransmitter in wild-type vs. dSERT N484D flies, drugtreated or untreated, and male vs. female.

2.4.1 5-HT results
5-HT is a neurotransmitter synthesized from the amino acid tryptophan. It
is involved in numerous core biological functions, including regulation of sleep
and wakefulness, appetite, and mood.62, 63 As it is the native substrate for SERT,
as well as a principal target for amphetamines, it was crucial to assess for
amphetamine-induced changes in levels of 5-HT. Previous in vitro data suggest
that dSERT is insensitive to MDMA.51 The N484D point mutation is proposed to
restore sensitivity to MDMA. Flies expressing dSERT N484D were therefore
expected to have time-dependent depletion of 5-HT after MDMA exposure, and
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indeed this was observed. The concentration of 5-HT was significantly reduced
in N484D flies relative to wild type when flies were treated with 0.05% MDMA
(figure 2.1 A, B, 2.2 A). Post-hoc analysis by multiple t-test using the HolmSidak method revealed that 0.05% MDMA significantly reduced 5-HT in N484D
flies at 6 and 24 hours. The effects were not yet observable after 2 hours, and
were no longer observed after 30 hours. Treatment with 0.6% MDMA produced
direct drug effects in both wild-type and N484D flies (figure 2.1 C, D), but did
not result in significant differences between the two (figure 2.2, B). METH
exposure produced direct drug effects in WT flies on 5-HT levels only at the 6
hour time point (figure 2.1 E), and no differences were observed between wildtype and N484D flies (figure 2.2 C).
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Figure 2.1 Direct Drug Effects on 5-HT concentrations in wild type and N484D
mutant flies. One sample t-test with a theoretical mean of 1.0 was performed to
assess for changes in neurotransmitter concentrations between drug-treated and
untreated flies to assess for drug response. No significant effects were observed
in Control Flies treated with 0.05% MDMA (Panel A). Significance was reached at
the 2 hour and 6 hour time points, P=0.0047 and 0.0479, respectively, for N484D
flies. Effects were present, but did not reach statistical significance by the 24
hour point, P=0.0640 (Panel B). Significant drug effects were also observed at all
times measured in wild-type flies treated with 0.6% MDMA, P ˂ 0.01, and at the 2
hour and 6 hour time points in N484D flies, P=0.0007 and 0.0262, respectively,
though they were also not observed by the 24 time point (Panels C and D). In
flies treated with 0.6% METH significant direct drug effects were reached only at
the 6 hour point in wild-type flies, P=0.0319 (Panels E and F). One sample was
measured as approximately 30 flies for each drug treatment at each time point.
Error bars represent the mean ± SEM of independent experiments for each time
point measured.
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Figure 2.2 Comparison of 5-HT concentrations in wild-type and N484D flies.
Two-Way ANOVA showed significantly reduced 5-HT levels in N484D flies
relative to wild-type after treatment with 0.05% MDMA, P= 0.0039 Post-hoc
analysis by multiple t-test using the Holm-Sidak method revealed that 5-HT was
reduced in N484D flies after 6 and 24 hours, P=0.02181 and 0.02536,
respectively (Panel A). Significant differences were not observed with 0.6%
MDMA treatment. (Panel B) Two-Way ANOVA failed to show a significant
reduction in 5-HT levels in N484D flies relative to wild-type after 0.6% METH
treatment:, P=0.6853 (Panel C).
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2.4.2 Results for Dopamine
DA is a neurotransmitter derived from the amino acid tyrosine. DA is the
neurotransmitter most commonly associated with the reinforcing properties of
addictive psychoactive substances, and is also involved in the coordination of
movement, reward, attention, memory, and motivation.64
Based on existing dating that amphetamines induce DA release,
amphetamine exposure was predicted to reduce concentrations of DA in fly
tissue samples. Drug-effects were observed in flies treated with 0.05% MDMA at
two time points, and at one time point in METH-treated flies (figure 2.3). TwoWay ANOVA showed significantly reduced DA levels in N484D flies relative to
wild-type, P=0.0262 (figure 2.4 A). However, no differences were observed in
flies treated with 0.6% MDMA (P = 0.7548) or with METH (P = 0.5431) (figure 2.4
B, C).
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Figure 2.3 Direct Drug Effects on DA concentrations in wild type and N484D
mutant flies. One sample t-test with a theoretical mean of 1.0 was performed to
assess for neurotransmitter concentrations between drug-treated and untreated
flies. No significant effects were observed in Control or N484D flies treated with
0.05% MDMA (Panels A and B). In wild-type flies treated with 0.6% MDMA,
significant drug effects were observed at the 6 and 24 hour time points P=0.0198
and 0.030, respectively. No effects were observed in N484D flies (Panels C and
D). In flies treated with 0.6% METH significant direct drug effects were reached
only at the 6 hour point in wild-type flies, P=0.0134, but not in N484D flies
(Panels E and F). One sample was measured as approximately 30 flies for each
drug treatment at each time point. Error bars represent the mean ± SEM of
independent experiments for each time point measured.
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Figure 2.4 Comparison of DA concentrations in wild-type and N484D flies. TwoWay ANOVA showed significantly reduced DA levels in N484D flies relative to
wild-type after 0.05%MDMA treatment, P=0.0262 (Panel A). However, no
differences were observed in flies treated with 0.6% MDMA (P = 0.7548) or with
METH (P = 0.5431) (Panels B and C).
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2.4.3 Norepinephrine, tyramine, octopamine, and gender results
It is well established that MDMA and METH have effects on the 5-HT, DA,
and NE systems in humans. As such, it was natural to study these
neurotransmitters. In mammals, NE Influences sleep, wakefulness, attention, and
feeding behavior.65 Although it is the key neurotransmitter in the sympathetic
nervous system in humans, NE is not present in D. melanogaster. In invertebrate
species, NE is functionally replaced by OCT. NE concentration was still analyzed
by HPLC/mass spectroscopy as a control assessing for contamination. In
mammals, NE is the principal neurotransmitter governing the sympathetic
nervous system. Found only in trace amounts, little is known about the function
of OCT in humans.66 In invertebrates, OCT is present in very high concentrations,
and is believed to be the principal invertebrate neurotransmitter67, making it
important to study changes in OCT levels in D. melanogaster. However, results
from this work found OCT in only very low concentrations, sometimes
undetectable by HPLC-MS/MS. Consequently, no drug effects, or differences
between wild-type or N484D flies were observed.
Additionally, interest in the trace amine tyramine (TYR) as a catecholaminereleasing agent contributing to the effects of drugs of abuse is increasing. TYR is
a trace amine derived from the amino acid tyrosine. It may induce
vasoconstriction and regulate blood pressure, and is essential for female sperm
storage, and for larval locomotion in D. melanogaster.66 It is known for having
moderate psychoactive effects associated with the consumption fermented foods,
particularly strong cheeses (e.g. blue cheese). As cheese is high in tyramine,
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excess consumption, especially in persons concurrently taking an MAOI, can
have psychoactive sympathomimetic effects.68 Much like OCT, TYR also has
effects on the adrenergic and dopaminergic systems.69 . It has been suggested
that TYR may act as a direct agonist of brain DA receptors.69 This makes the role
of tyramine in amphetamine-induced changes in neurochemistry important to
examine. No significant differences were observed between WT D. melanogaster
and N484D mutants in respect to TYR or OCT concentrations in this study.
Lastly, it was unknown if gender-specific differences would be observed
amongst drug-treated flies. No differences were observed between male and
female flies in the drug-treated or untreated groups.
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CHAPTER 3. DISCUSSION

3.1

Discussion of results

Amphetamines are a class of potent psychoactive drugs that are used for
both therapeutic and recreational purposes. The pharmacological activity of
amphetamines is mainly caused by their action on monoamine neurotransmitter
systems. In particular, a reversal of the transport cycle of the monoamine
transporters SERT, DAT, and NET leads to increased synaptic concentrations of
neurotransmitters, and contributes to their psychoactivity.68
Previous research has shown that dSERT is insensitive to MDMA.51, 70
However, a dSERT point mutation (N484D) has been identified that restores
sensitivity to MDMA in vitro. Here, an in vivo analysis of the effects of MDMA and
METH exposure on biogenic amine levels in wild-type flies and flies expressing
dSERT N484D was performed. Results showed that treatment with 0.05%
MDMA significantly reduced 5-HT levels in dSERT N484D flies relative to wildtype flies. As significant drug-induced changes were not observed in the levels of
other neurotransmitters investigated, it may be that the effects of this mutation in
dSERT exclusively influence 5-HT levels. This was particularly clear in
experiments with MDMA, which has greater affinity for SERT relative to other
amphetamines.2, 45 Although lower DA content was observed in N484D flies than
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wild-type flies treated with 0.05% MDMA (figure 2.4 A), this was not the result of
drug effects (figure 2.3 A, B).
Previous in vitro work performed in the Barker laboratory show that the
N484D mutation restores amphetamine-induced efflux to dSERT. Without the
presence of an acidic residue to create a functional salt bridge between the two
transmembrane helices, wild-type dSERT exhibits minimal responsiveness to
amphetamines. When the salt bridge is restored by the mutation of asparagine
484 to an aspartate this functionality is also reintroduced. The results for 0.05%
MDMA-treated flies complement this in vitro data from the Barker lab suggesting
an essential role for this salt bridge in mediating the ability of amphetamines to
be substrates for SERT, and underline the importance of this specific residue in
the native function of SERT. However, the lack of a response to 0.6% MDMA and
0.6% METH was unexpected.
Though a large number of flies were used (approximately 30 flies per data
point), no more than 6 data points were generated for any time point, and most
had only 2 or 3. It may be that significant changes were not observed due to this
relatively small sample size, potentially skewing the results. Much of the data did
not show the predicted changes in neurochemistry. However, it is noteworthy that
where the predicted changes were observed, the trend was for N484D flies to
have lower neurotransmitter levels than wild-type flies (e.g. figure 2.1 A, B). It
may be that with a greater number of replicates at each time point more
conclusive results could be generated.
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Additionally, this in vivo model used a transgenic targeted expression
system that inserted dSERT N484D into D. melanogaster without altering native
dSERT. This may pose a potential limitation to this study, as the presence of
dSERT may confound the interpretation of results (i.e. a lack of detectable effects
may be due to native dSERT mitigating drug effects mediated by dSERT N484D).
The relative abundance of either protein was not assessed, so the extent of
dSERT involvement was not determined. However, it is important to note that
although dSERT was present it would still be expected that amphetamines would
inhibit uptake by dSERT, allowing for neurotransmitter efflux through dSERT
N484D to lead to drug-induced neurochemical changes.

3.2

Future directions

The present study examined the role of a conserved acidic residue in SERT
in vivo by analyzing changes in neurochemistry in D. melanogaster expressing
the N484D mutant transporter after MDMA or METH exposure. After completing
these studies, experiments using D. melanogaster tissue for the generation of
synaptosomes were attempted. Synaptosomes are a useful way to study the
activity of proteins involved in neurotransmission.71 This could be used to provide
an alternative means of assessing drug-induced changes in D. melanogaster
neurochemistry. Synaptosomes are routinely prepared from mammalian tissue
for laboratory studies. To our knowledge, only one report exists wherein D.
melanogaster tissue was used for synaptosome generation. 72 Using
invertebrates rather than mammals for synaptosome preparation requires
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considerably more samples to yield sufficient quantities of tissue, and is more
difficult to complete.73 Efforts to make synaptosomes from D. melanogaster have
thus far been unsuccessful.
Additionally, it was observed in these experiments that all flies treated with
MDMA or METH seemed to respond to treatment in terms of locomotor activity,
irrespective of whether they were wild-type or N484D. However, this behavior
was not measured quantitatively. Future behavioral studies would also be useful
to further understand amphetamine pharmacology and the role of this salt bridge
in restoring MDMA sensitivity in D. melanogaster. Experiments previously
performed in the Pittendrigh laboratory using 0.6% METH showed increased
locomotor activity. It would be predicted that while wild-type flies would not
respond after MDMA treatment, owing to dSERT insensitivity to MDMA, N484D
flies would have increased locomotion.
Lastly, D. melanogaster has previously been used to study genomic,
proteomic, and transcriptomic changes after exposure to METH.15 This model
could also be extended to MDMA to observe systems level changes resulting
from MDMA-induced 5-HT depletion in N484D flies. Future research using this
model is likely to be useful fighting amphetamine addiction and toxicity.
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Table A1.Biogenic amines structures and functions

Biogenic amine

Dopamine

Norepinephrine

Octopamine

Structure

Function
Involved in coordination of movement, reward
and motivation. Many addictive drugs
stimulate dopamine release, and this is
believed to be a crucially involved in
addiction.64
Influences sleep, wakefulness, attention, and
feeding behavior. Although it is the key
neurotransmitter in the sympathetic nervous
system in humans it is not present in
Drosophila.65

Found only in trace amounts in humans. Little
is known about its function. The main
neurotransmitter in invertebrates. Replaces
norepinephrine in the sympathetic nervous
system.66 Essential for female sperm storage,
and larval locomotion.67

Serotonin

Involved in numerous core biological
functions, including regulation of sleep and
wakefulness, appetite, and mood.62

Tyramine

A trace amine which acts as a catecholaminereleasing agent. May induce vasoconstriction
and regulate blood pressure. Essential for
female sperm storage, and for larval
locomotion in D. melanogaster.66
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